IP Library Granted Patent US 8,962,255
Granted Patent B2
US 8,962,255 · App. 14/033,679 · Granted Feb 24, 2015

Recombinase polymerase amplification

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,962,255
App. No.
14/033,679
Granted
Feb 24, 2015
Kind
B2
Abstract

This disclosure describes related novel methods for Recombinase-Polymerase Amplification (RPA) of a target DNA that exploit the properties of recombinase and related proteins, to invade double-stranded DNA with single stranded homologous DNA permitting sequence specific priming of DNA polymerase reactions. The disclosed methods have the advantage of not requiring thermocycling or thermophilic enzymes. Further, the improved processivity of the disclosed methods may allow amplification of DNA up to hundreds of megabases in length.

Claims (51)

1. A composition comprising:

(1) at least one recombinase;

(2) at least one polymerase;

(3) a target nucleic acid;

(4) a crowding agent; and

(5) a first nucleic acid primer and optionally a second nucleic acid primer.

2. The composition of claim 1 , wherein the at least one recombinase is selected from the group consisting of UvsX, RecA, and combinations thereof.

3. The composition of claim 1 , wherein the at least one polymerase includes at least one DNA polymerase which lacks 3′-5′ exonuclease activity.

4. The composition of claim 1 , wherein the at least one polymerase comprises a DNA polymerase with strand displacing properties.

5. The composition of claim 1 , wherein the crowding agent is present at a concentration between 1 to 12% of a weight or a volume of the composition.

6. The composition of claim 1 , wherein the crowding agent is selected from the group consisting of polyethylene glycols, dextran, ficoll and a combination thereof.

7. The composition of claim 6 , wherein the crowding agent comprises polyethylene glycol at a concentration between 1 to 12% of a weight or a volume of the composition.

8. The composition of claim 6 , wherein said polyethylene glycol is selected from the group consisting of PEG1450, PEG3000, PEG8000, PEG10000, PEG compound (molecular weight 15,000 to 20,000), and combinations thereof.

9. The composition of claim 1 , wherein the first and second nucleic acid primers are selected from the group consisting of DNA, RNA, PNA, LNA, morpholino backbone nucleic acid, phosphorothiorate backbone nucleic acid, and a combination thereof.

10. The composition of claim 1 , further comprising at least one recombinase loading protein.

11. The composition of claim 10 , wherein the recombinase loading protein is selected from the group consisting of T4 uvsY, E. coli recO, E. coli recR and combinations thereof.

12. The composition of claim 10 , wherein the recombinase loading protein is present at a concentration of between 0.2 μM and 8 μM.

13. The composition of claim 1 , wherein the at least one polymerase is selected from the group consisting of prokaryotic polymerase, eukaryotic polymerase and phage-encoded polymerase.

14. The composition of claim 13 , wherein said eukaryotic polymerase is selected from the group consisting of pol-α, pol-β, pol-δ, and a combination thereof.

15. The composition of claim 13 , wherein the procaryotic polymerase is selected from the group consisting of E. coli DNA polymerase I Klenow fragment, bacteriophage T4 gp43 DNA polymerase, Bacillus stearothermophilus polymerase I large fragment, Phi-29 DNA polymerase, T7 DNA polymerase, Bacillus subtilis Pol I large fragment (Bsu polymerase), E. coli DNA polymerase I, E. coli DNA polymerase II, E. coli DNA polymerase III, E. coli DNA polymerase IV, E. coli DNA polymerase V and a combination thereof.

16. The composition of claim 1 , wherein the recombinase is in contact with the first nucleic acid primer to form a nucleoprotein primer.

17. The composition of claim 1 , wherein the composition comprises a first nucleic acid primer and a second nucleic acid primer.

18. The composition of claim 17 , further comprising a third nucleic acid primer.

19. The composition of claim 18 , further comprising a fourth nucleic acid primer.

20. The composition of claim 17 , wherein the recombinase is in contact with the nucleic acid primers to form a first and a second nucleoprotein primer.

21. The composition of claim 1 , wherein the recombinase is temperature-sensitive.

22. The composition of claim 1 , further comprising at least one single stranded DNA binding protein.

23. The composition of claim 22 , wherein said single stranded DNA binding protein is selected from the group consisting of E. coli SSB, T4 gp32 and combinations thereof.

24. The composition of claim 1 , further comprising ATP or an ATP analog.

25. The composition of claim 1 , further comprising dNTPs or a mixture of dNTPs and ddNTPs.

26. The composition of claim 1 , further comprising a buffer.

27. The composition of claim 1 , wherein the target nucleic acid comprises a double stranded target sequence.

28. The composition of claim 1 , wherein the target nucleic acid comprises a single stranded target sequence.

29. The composition of claim 16 , wherein the first nucleic acid primer comprises a 3′ blocking group.

30. The composition of claim 18 , wherein at least one primer comprises a 3′ blocking group.

31. A kit comprising:

(1) at least one recombinase;

(2) at least one polymerase; and

(3) a crowding agent.

32. The kit of claim 31 , further comprising a first nucleic acid primer and optionally a second nucleic acid primer.

33. The kit of claim 31 , further comprising dNTPs or a mixture of dNTPs and ddNTPs.

34. The kit of claim 31 , further comprising a buffer, and/or ATP or ATP analog.

35. The kit of claim 31 , further comprising a third primer and optionally a fourth primer.

36. The kit of claim 31 , wherein the crowding agent is selected from the group consisting of polyethylene glycols, dextran, ficoll and a combination thereof.

37. A reagent mixture for nucleic acid amplification comprising:

(1) at least one recombinase;

(2) at least one polymerase; and

(3) a crowding agent.

38. The reagent mixture of claim 37 , further comprising dNTPs or a mixture of dNTPs and ddNTPs.

39. The reagent mixture of claim 37 , further comprising a buffer, and/or ATP or ATP analog.

40. A composition comprising: the reagent mixture of claim 37 ; a target nucleic acid; and at least one nucleic acid primer.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 10, 2020
From: ALERE SAN DIEGO INC.
To: ABBOTT DIAGNOSTICS SCARBOROUGH, INC.
Reel/Frame 054604/0936 →
RELEASE OF SECURITY INTEREST IN INTELLECTUAL PROPERTY RECORDED AT REEL 036994, FRAME 0192 AND REEL 037115, FRAME 0498 Recorded Oct 5, 2017
From: HEALTHCARE FINANCIAL SOLUTIONS, LLC, AS COLLATERAL AGENT
To: ALERE CONNECT, LLC; ALERE SAN DIEGO, INC. (FKA BIOSITE INC. OR FKA CHOLESTECH CORP. OR FKA HEMOSENSE INC. OR FKA INVERNESS MEDICAL-BIOSTAR INC. OR FKA ISCHEMIA TECHNOLOGIES, INC. OR FKA TWISTDX, INC.); ALERE SCARBOROUGH, INC. (FKA MATRITECH, INC. FKA ADVANTAGE DIAGNOSTICS CORP. OR FKA BINAX, INC. OR FKA MILANO ACQUISITION CORP.); INNOVACON, INC. (FKA APPLIED BIOTECH, INC. OR FKA AMEDITECH INC.); IONIAN TECHNOLOGIES, LLC (FKA IONIAN TECHNOLOGIES, INC.); QUALITY ASSURED SERVICES INC. (FKA ZYCARE INC.); STANDING STONE, LLC; ESCREEN, INC.
Reel/Frame 044213/0258 →
ASSIGNMENT OF IP SECURITY AGREEMENT, PREVIOUSLY RECORDED AT REEL 036994, FRAME 0192 Recorded Nov 16, 2015
From: GENERAL ELECTRIC CAPITAL CORPORATION, AS RETIRING ADMINISTRATIVE AGENT
To: HEALTHCARE FINANCIAL SOLUTIONS, LLC, AS SUCCESSOR ADMINISTRATIVE AGENT
Reel/Frame 037115/0498 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Oct 29, 2015
From: ALERE CONNECT, LLC; ALERE SAN DIEGO, INC. (FKA BIOSITE INC. OR FKA CHOLESTECH CORP. OR FKA HEMOSENSE INC. OR FKA INVERNESS MEDICAL-BIOSTAR INC. OR FKA ISCHEMIA TECHNOLOGIES, INC. OR FKA TWISTDX, INC.); ALERE SCARBOROUGH, INC. (FKA MATRITECH, INC. FKA ADVANTAGE DIAGNOSTICS CORP. OR FKA BINAX, INC. OR FKA MILANO ACQUISITION CORP.); INNOVACON, INC. (FKA APPLIED BIOTECH, INC. OR FKA AMEDITECH INC.); IONIAN TECHNOLOGIES, LLC (FKA IONIAN TECHNOLOGIES, INC.); QUALITY ASSURED SERVICES INC. (FKA ZYCARE INC.); STANDING STONE, LLC; ESCREEN, INC.
To: GENERAL ELECTRIC CAPITAL CORPORATION, AS COLLATERAL AGENT
Reel/Frame 036994/0192 →